JP2009536834A - 癌の診断及び治療のための方法及び組成物 - Google Patents

癌の診断及び治療のための方法及び組成物 Download PDF

Info

Publication number
JP2009536834A
JP2009536834A JP2009511179A JP2009511179A JP2009536834A JP 2009536834 A JP2009536834 A JP 2009536834A JP 2009511179 A JP2009511179 A JP 2009511179A JP 2009511179 A JP2009511179 A JP 2009511179A JP 2009536834 A JP2009536834 A JP 2009536834A
Authority
JP
Japan
Prior art keywords
fgfr2
antibody
gene
colorectal cancer
antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009511179A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009536834A5 (enExample
Inventor
ジョン チャント，
アンソニー エス． ゲレロ，
ピーター ハヴァティ，
シンシア ホンチェル，
ケニス ユング，
トーマス ウー，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of JP2009536834A publication Critical patent/JP2009536834A/ja
Publication of JP2009536834A5 publication Critical patent/JP2009536834A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2009511179A 2006-05-12 2007-05-11 癌の診断及び治療のための方法及び組成物 Pending JP2009536834A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79977206P 2006-05-12 2006-05-12
PCT/US2007/068737 WO2007134210A2 (en) 2006-05-12 2007-05-11 Methods and compositions for the diagnosis and treatment of cancer

Publications (2)

Publication Number Publication Date
JP2009536834A true JP2009536834A (ja) 2009-10-22
JP2009536834A5 JP2009536834A5 (enExample) 2010-07-01

Family

ID=38694721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009511179A Pending JP2009536834A (ja) 2006-05-12 2007-05-11 癌の診断及び治療のための方法及び組成物

Country Status (5)

Country Link
US (2) US8945572B2 (enExample)
EP (1) EP2018442A2 (enExample)
JP (1) JP2009536834A (enExample)
CA (1) CA2651755A1 (enExample)
WO (1) WO2007134210A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
WO2014007369A1 (ja) * 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Ｆｇｆｒ２融合遺伝子

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565511A (en) 2005-07-22 2011-03-31 Five Prime Therapeutics Inc Compositions and methods of treating disease with FGFR fusion proteins
US8945572B2 (en) 2006-05-12 2015-02-03 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer
CN102171343B (zh) 2008-08-04 2017-07-14 戊瑞治疗有限公司 Fgfr细胞外结构域酸性区突变蛋白
DK3290052T3 (da) * 2008-11-07 2020-02-03 Galaxy Biotech Llc Monoklonale antistoffer mod fibroblastvækstfaktorreceptor 2
US20100136560A1 (en) * 2008-12-02 2010-06-03 The Johns Hopkins University Integrated Analyses of Breast and Colorectal Cancers
WO2011025814A1 (en) * 2009-08-25 2011-03-03 National Jewish Health Methods and compositions for treatment of lung injury
WO2011034940A1 (en) 2009-09-15 2011-03-24 Five Prime Therapeutics, Inc. Hair growth methods using fgfr4 extracellular domains
PT2498799T (pt) 2009-11-13 2016-11-04 Five Prime Therapeutics Inc Utilização de proteínas do domínio extracelular rfcf1 para tratar cancros caracterizados por mutações ativadoras dependentes de ligando em rfcf2
WO2011084711A2 (en) 2009-12-17 2011-07-14 Five Prime Therapeutics, Inc. Hair growth methods using fgfr3 extracellular domains
US8481038B2 (en) 2010-11-15 2013-07-09 Five Prime Therapeutics, Inc. Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins
US8951972B2 (en) 2010-12-09 2015-02-10 Five Prime Therapeutics, Inc. FGFR1 extracellular domain combination therapies for lung cancer
EP2723924A4 (en) * 2011-06-22 2015-03-25 Oncocyte Corp METHOD AND COMPOSITIONS FOR THE TREATMENT AND DIAGNOSIS OF CANCER
WO2013074492A1 (en) 2011-11-14 2013-05-23 Five Prime Therapeutics, Inc. Methods of treating cancer
MX2014007121A (es) * 2011-12-14 2014-09-04 Seattle Genetics Inc Nuevos conjugados de principio activo-ligante (adc) y su uso.
US9415118B2 (en) * 2013-03-13 2016-08-16 Novartis Ag Antibody drug conjugates
US9498532B2 (en) 2013-03-13 2016-11-22 Novartis Ag Antibody drug conjugates
MX374785B (es) 2013-08-01 2025-03-06 Five Prime Therapeutics Inc Anticuerpos anti-fgfr2iiib afucosilados.
SG10201913538VA (en) * 2015-11-23 2020-02-27 Five Prime Therapeutics Inc Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
DK3624837T3 (da) 2017-05-16 2025-09-29 Five Prime Therapeutics Inc Anti-fgfr2-antistoffer i kombination med kemoterapeutiske midler til kræftbehandling

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863888A (en) 1990-07-06 1999-01-26 Rhone-Poulenc Rorer Pharmaceuticals Inc. Human Bek Fibroblast growth factor receptor
US6900053B2 (en) 2001-09-14 2005-05-31 Isis Pharmaceuticals, Inc. Antisense modulation of fibroblast growth factor receptor 2 expression
WO1999044062A1 (en) * 1998-02-25 1999-09-02 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cellular arrays for rapid molecular profiling
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
US6335155B1 (en) 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1131470A4 (en) * 1998-10-28 2004-11-10 Vysis Inc CELLULAR ARRAYS AND METHOD FOR DETECTING AND USING MARKERS FOR GENETIC DISORDERS
CA2355215A1 (en) 1998-12-28 2000-07-06 Jim Wells Identifying small organic molecule ligands for binding
IL128380A0 (en) 1999-02-04 2000-01-31 Yeda Res & Dev A method of screening for agonists and antagonists of FGFR
US7442776B2 (en) * 1999-10-08 2008-10-28 Young David S F Cancerous disease modifying antibodies
AU2001275337A1 (en) 2000-06-07 2001-12-17 Lexicon Genetics Incorporated Novel human transporter proteins and polynucleotides encoding the same
US7361343B2 (en) * 2003-01-21 2008-04-22 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of CD63
US7537905B2 (en) 2003-01-15 2009-05-26 The Regents Of The University Of California Amplified and overexpressed gene in colorectal cancers
US7393531B2 (en) * 2003-01-21 2008-07-01 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of MCSP
WO2005066211A2 (en) 2003-12-19 2005-07-21 Five Prime Therapeutics, Inc. Fibroblast growth factor receptors 1, 2, 3, and 4 as targets for therapeutic intervention
EP1773305A2 (en) * 2004-05-25 2007-04-18 Yale University Corporation Method for treating skeletal disorders resulting from fgfr malfunction
CA2604844A1 (en) 2005-04-07 2006-10-19 Novartis Vaccines And Diagnostics, Inc. Cancer-related genes
US8945572B2 (en) * 2006-05-12 2015-02-03 Genentech, Inc. Methods and compositions for the diagnosis and treatment of cancer

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
JPN6012029531; Ｎａｔｕｒｅ，　１９９９，　４０２，　ｐｐ．７１５-７２０ *
JPN6012036803; Ｐａｔｈｏｌ．　Ｉｎｔ．，　２０００，　５０（５），　ｐｐ．３６３-３７２ *
JPN6012036805; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ．，　１９９６，　２（８），　ｐｐ．１３７３-１３８１ *
JPN6012036808; Ｂｒｅａｓｔ　Ｃａｎｃｅｒ　Ｒｅｓ．，　２０００，　２（４），　ｐｐ．３１１-３２０ *
JPN6012036810; Ｃｌｉｎ．　Ｃａｎｃｅｒ　Ｒｅｓ．，　２００３，　９（１４），　ｐｐ．５２７１-５２８１ *
JPN6012036812; Ｊ．　Ｎｉｈｏｎ　Ｍｅｄ．　Ｓｃｈ．，　２００１，　６８（５），　ｐｐ．３９７-４０４ *
JPN6012036814; Ｏｎｃｏｇｅｎｅ，　２００４，　２３（５７），　ｐｐ．９２０１-９２１１ *
JPN6012036815; Ｊ．　Ｂｉｏｌ．　Ｃｈｅｍ．，　１９９３，　２６８（１３），　ｐｐ．９１８０-９１８３ *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529076A (ja) * 2010-05-11 2013-07-18 アベオ ファーマシューティカルズ， インコーポレイテッド 抗ｆｇｆｒ２抗体
WO2014007369A1 (ja) * 2012-07-05 2014-01-09 独立行政法人国立がん研究センター Ｆｇｆｒ２融合遺伝子

Also Published As

Publication number Publication date
US8945572B2 (en) 2015-02-03
WO2007134210A8 (en) 2009-07-30
US20090311250A1 (en) 2009-12-17
CA2651755A1 (en) 2007-11-22
WO2007134210A3 (en) 2008-03-20
US20150167101A1 (en) 2015-06-18
WO2007134210A2 (en) 2007-11-22
EP2018442A2 (en) 2009-01-28

Similar Documents

Publication Publication Date Title
US8945572B2 (en) Methods and compositions for the diagnosis and treatment of cancer
JP2010509922A (ja) 腫瘍と関連している遺伝的変異
NZ563370A (en) Compositions and methods for the diagnosis and treatment of tumor
EP2592156A2 (en) Gene expression markers of tumor resistance to HER2 inhibitor treatment
JP2012177698A (ja) 癌の予後予測方法、診断方法及び治療方法
JP5596975B2 (ja) 腫瘍と関連している遺伝的変異
US20090098115A1 (en) Cell lines and animal models of HER2 expressing tumors
US20150376289A1 (en) Methods and compositions for the diagnosis and treatment of cancer
JP5297375B2 (ja) 癌の診断及び治療のための方法及び組成物
HK1108924B (en) Cancer prognostic methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121017

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121024

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121119

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130118

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130514